Cardiff Oncology Inc’s filing revealed that its Chief Financial Officer Levine James E. acquired Company’s shares for reported $14905.0 on Dec 17 ’24. In the deal valued at $5.42 per share,2,752 shares were bought. As a result of this transaction, Levine James E. now holds 65,316 shares worth roughly $0.18 million.
Then, Levine James E. bought 2,400 shares, generating $12,000 in total proceeds. Upon buying the shares at $5.00, the Chief Financial Officer now owns 67,716 shares.
Before that, Levine James E. bought 2,564 shares. Cardiff Oncology Inc shares valued at $9,820 were divested by the Chief Financial Officer at a price of $3.83 per share. As a result of the transaction, Levine James E. now holds 62,564 shares, worth roughly $0.17 million.
Craig Hallum initiated its Cardiff Oncology Inc [CRDF] rating to a Buy in a research note published on September 06, 2024; the price target was $8. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Robert W. Baird began covering CRDF with “an Outperform” recommendation on December 08, 2021.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock jump 3.38% to $2.75. Over the last five days, the stock has gained 2.61%. Cardiff Oncology Inc shares have fallen nearly -36.64% since the year began. Nevertheless, the stocks have fallen -14.06% over the past one year. While a 52-week high of $5.64 was reached on 02/21/25, a 52-week low of $2.01 was recorded on 04/11/25. SMA at 50 days reached $3.19, while 200 days put it at $3.15.
Levels Of Support And Resistance For CRDF Stock
The 24-hour chart illustrates a support level at 2.60, which if violated will result in even more drops to 2.45. On the upside, there is a resistance level at 2.90. A further resistance level may holdings at 3.06. The Relative Strength Index (RSI) on the 14-day chart is 45.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.63%. Stochastics %K at 30.23% indicates the stock is a holding.
The most recent change occurred on October 22, 2020 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
